EDAP TMS S.A. (EDAP)
NASDAQ: EDAP · IEX Real-Time Price · USD
5.95
+0.18 (3.12%)
May 31, 2024, 4:30 PM EDT - Market closed
EDAP TMS Revenue
EDAP TMS had revenue of $65.80M in the twelve months ending March 31, 2024, with 6.38% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $16.20M with 0.76% year-over-year growth. In the year 2023, EDAP TMS had annual revenue of $67.14M with 14.52% growth.
Revenue (ttm)
$65.80M
Revenue Growth
+6.38%
P/S Ratio
3.36
Revenue / Employee
$214,332
Employees
307
Market Cap
220.77M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 67.14M | 8.51M | 14.52% |
Dec 31, 2022 | 58.63M | 8.55M | 17.08% |
Dec 31, 2021 | 50.07M | -733.45K | -1.44% |
Dec 31, 2020 | 50.81M | 344.40K | 0.68% |
Dec 31, 2019 | 50.46M | 5.42M | 12.05% |
Dec 31, 2018 | 45.04M | 2.14M | 4.99% |
Dec 31, 2017 | 42.90M | 5.42M | 14.46% |
Dec 31, 2016 | 37.48M | 2.45M | 6.98% |
Dec 31, 2015 | 35.03M | 2.62M | 8.09% |
Dec 31, 2014 | 32.41M | -705.63K | -2.13% |
Dec 31, 2013 | 33.11M | -1.27M | -3.69% |
Dec 31, 2012 | 34.38M | 5.52M | 19.14% |
Dec 31, 2011 | 28.86M | -2.84M | -8.96% |
Dec 31, 2010 | 31.70M | -3.98M | -11.17% |
Dec 31, 2009 | 35.68M | 3.55M | 11.06% |
Dec 31, 2008 | 32.13M | -508.42K | -1.56% |
Dec 31, 2007 | 32.64M | 5.97M | 22.39% |
Dec 31, 2006 | 26.66M | 2.08M | 8.44% |
Dec 31, 2005 | 24.59M | -5.46M | -18.18% |
Dec 31, 2004 | 30.05M | 6.79M | 29.19% |
Dec 31, 2003 | 23.26M | 2.32M | 11.06% |
Dec 31, 2002 | 20.95M | -356.44K | -1.67% |
Dec 31, 2001 | 21.30M | -4.21M | -16.50% |
Dec 31, 2000 | 25.51M | 5.04M | 24.64% |
Dec 31, 1999 | 20.47M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Akebia Therapeutics | 187.23M |
908 Devices | 50.73M |
Scilex Holding Company | 47.05M |
Werewolf Therapeutics | 16.22M |
Ovid Therapeutics | 473.54K |
EDAP News
- 26 days ago - EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting - GlobeNewsWire
- 4 weeks ago - EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024 - GlobeNewsWire
- 5 weeks ago - EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting - GlobeNewsWire
- 2 months ago - EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 - GlobeNewsWire
- 3 months ago - EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference - GlobeNewsWire
- 3 months ago - EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis - GlobeNewsWire
- 3 months ago - EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues - GlobeNewsWire
- 5 months ago - EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements - GlobeNewsWire